Advanz Pharma News and Activities

Advanz Pharma is a company listed under the stock ticker CXRXF (CA).

Advanz Pharma has a direct presence in 2 countries.

View the org chart displaying its 18 main executives

Most searched biographies at Advanz Pharma

• Steffen Wagner, Chief Executive Officer and Director
• Rainer Lenhard, Director
• Raj Shah, Director

Create your alert
to follow the executive moves at Advanz Pharma.

Advanz Pharma has 1,827 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• Juvenescence has just announced a $76 Million fundraising (posted on May 22 2025).
• Kincell Bio has just announced a $22 Million fundraising (posted on May 22 2025).
• Danone has announced the acquisition of Kate Farms  (posted on May 14 2025).

Popular contacts in Pharmaceuticals

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets at Bristol-Myers Squibb
• Seth Harrison - Chairman and Director at Braeburn Pharmaceuticals
• Fred Davenport - Lead Director at Medpace

Learn more about the Pharmaceuticals industry

Press releases by Advanz Pharma

• ADVANZ PHARMA acquires the rights to Progynova® and Cyclo-Progynova® in selected countries in APAC from Bayer | ADVANZ PHARMA
• ADVANZ PHARMA’s response to the reversal of the suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe | ADVANZ PHARMA
• European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) | ADVANZ PHARMA
• ADVANZ PHARMA acquires the rights to Nootropil® and Atarax® from UCB for Europe and selected countries in LATAM and APAC | ADVANZ PHARMA
• ADVANZ PHARMA Releases Environmental, Social & Governance (ESG) Report for 2023-2024 | ADVANZ PHARMA
• ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC) | ADVANZ PHARMA
• ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe | ADVANZ PHARMA
• ADVANZ PHARMA and Enzene Enter an Exclusive Partnership for Biosimilar Development and Commercialisation | ADVANZ PHARMA
• European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) | ADVANZ PHARMA
• ADVANZ PHARMA response to CHMP recommendation pertaining to EU conditional marketing authorization for OCALIVA® in rare disease Primary Biliary Cholangitis | ADVANZ PHARMA
• View more press releases Close

Social media about Advanz Pharma

• Advanz Pharma on Wikipedia, Google News & Yahoo Finance
• Advanz Pharma on LinkedIn, Twitter & YouTube